AZ replants R&D roots in China, goes all-in on innovation

AstraZeneca throws weight behind China innovation while several peers focus on commercialization

In a big week for MNCs in China, AstraZeneca defined the latest move in its China strategy with an ‘all-in’ approach to innovation that goes full throttle by fostering R&D, AI and company formation.

As MNCs twist and turn on how best to participate in China’s growing biopharma sector and tap its increasingly important market, AstraZeneca plc (LSE:AZN; NYSE:AZN) is charting a different course from some its peers.

AZ’s Nov. 6 announcement of a $1 billion-targeted fund to invest in innovative healthcare companies in or focused on China, coupled with a new R&D center, an AI center and a slew of licensing deals, sees the company take an active role in fostering the growth of the emerging ecosystem.

“The new fund will

Read the full 1199 word article

User Sign In